Frontiers in Cardiovascular Drug Discovery is a book series devoted to publishing the latest advances in cardiovascular drug design and discovery. Each volume brings reviews on the biochemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships of molecules used in cardiovascular therapy. The book series should prove to be of great interest to all medicinal chemists and pharmaceutical scientists involved in preclinical and clinical research in cardiology.
Volume 6 covers the following topics:
- Cardiovascular effects of ranolazine and the scope for translational research: a current review of literature
- Rho/Rho kinase signaling pathway and disease:
- Hibernation or transformation? Challenges in cardiovascular drug development
- New approaches in P2Y12 receptor blocker drugs use
- Pathophysiological links between diabetes and cardiovascular diseases: at the biochemical and molecular levels
Table of Contents
Chapter 1 Cardiovascular Effects of Ranolazine and the Scope for Translational Research: a Current Review of Literature- Rebecca Pratiti, Parul Sud, Mohammad Yousef and Ankush Moza Ranolazine
- Mechanism of Action
- Effects on Late Sodium Current
- Effect on Metabolism
- Dosage Formulations, Pharmacodynamics and Pharmacokinetics
- Side Effects
- General Side Effects
- Tolerability of Ranolazine
- Drug-Drug Interaction
- Qt-Prolonging Effects
- Animal Studies
- Chronic Stable Angina (Csa)
- Acute Coronary Syndrome (Acs)
- Atrial Fibrillation
- Rhythm Control for Atrial Fibrillation in the Presence and Absence of Other Medications 24 Post-Operative Atrial Fibrillation (Poaf) in Patients Undergoing Cardiac Surgery
- Cardiomyopathy
- Chemotherapy-Induced Cardiomyopathy
- Hypertrophic Cardiomyopathy
- Arrhythmias
- Long Qt Syndromes (Lqts 3)
- Pathophysiology
- Efficacy
- Heart Failure (Hf)
- Pathophysiology
- Heart Failure With Preserved Ejection Fraction (Diastolic)
- Heart Failure With Reduced Ejection Fraction (Systolic)
- Glycemic Effects
- Mechanism of Action
- Effect on Glycated Hemoglobin A1C (Hba1C)
- Modifier Effect of Metformin
- Other Additional Effects of Ranolazine
- Future Implications
- Gaps in Translational Research
- Possible Causes of Inefficacy in Studies
- Conclusion and Summary
- List of Abbreviations
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
- Introduction
- Biological Effects of Rho Protein
- Rho Protein Classification
- Rho Protein Structure and Activity Regulation
- Downstream Effector Molecules of Rho
- Rho Kinase
- Structure and Classification of Rho Kinases
- Regulation Mechanism of Rho Kinase Activity
- Rho Kinase Inhibitor
- Rho/Rho Kinase and Cardiovascular Disease
- Rho/Rho Kinase and Hypertension
- Rho/Rho Kinase and Pulmonary Hypertension
- Rho/Rho Kinase and Atherosclerosis
- Rho/Rho Kinase and Myocardial Ischemia Reperfusion Injury
- Rho/Rho Kinase and Adriamycin-Induced Heart Injury
- Outlook
- Rho Kinase and Ischemic Cerebrovascular Disease
- The Mechanism of Rho Kinase in Cerebral Ischemia
- Rho Kinase Mediates Oxidative Stress
- Rho Kinase Mediated Cytoskeleton Changes
- Rho Kinase Mediates Inflammatory Response
- Rho Kinase Regulates Phosphatidylinositol Metabolism
- Rho Kinase Regulates the Expression of Enos
- Rho Kinase Regulates the Expression of Matrix Metalloproteinase-9
- Neuroprotective Effect of Rho Kinase Inhibitor
- Outlook
- Rho Kinase and Respiratory Diseases
- Rho Kinase and Copd
- Rho Kinase and Asthma
- Rho Kinase and Ipf
- Rho Kinase and Lung Cancer
- Conclusion and Prospect
- Rho Kinases in Immune Cells and Autoimmune Diseases
- Rho/Rock Signaling Pathway in Systemic Lupus Erythematosus
- Rho/Rock Signaling Pathway in Rheumatoid Arthritis
- Rho/Rock Signaling Pathway in Systemic Sclerosis
- Conclusion
- Rho and Chronic Kidney Disease
- Rho/Rock in 5/6 Nephrectomy and Unilateral Ureteral Ligation Model
- Rho/Rock in Hypertensive Nephropathy Animal Model
- Rho/Rock in Diabetic Animal Model
- Rho/Rock in Contrast Medium Induced Kidney Injury Model
- Rho and Portal Hypertension
- Outlook
- Conclusion
- Abbreviations
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
- Introduction
- Developing New Drugs in the 21 St Century
- Challenges in Drug Development and Their Reflections on the Cardiovascular Field
- Discovery and Development
- Challenges in Strategic Decision Making
- Challenges in Preclinical Trials
- Clinical Development
- Challenges in Clinical Trials
- Regulatory Approval
- Regulatory Uncertainty
- Health-Related Economic Challenges
- Financial Challenges
- Return Potential of Investment
- Patent Cliff
- Insufficient Incentives (Funding)
- Insufficient Investment
- Late-Stage Failures
- Conclusion and Future Perspective
- Consent for Publication
- Conflict of Interest
- Acknowledgments
- References
- Dolunay Merve Fakioğlu and Sevgi Akaydin Primary and Secondary Hemostasis
- P2Y1 and P2Y12 (Adp Receptors)
- P2Y12 Receptor Inhibitors and Potential Clinical Use
- Stable Ischemic Heart Disease
- Acute Coronary Syndromes
- Secondary Prevention of Ischemic Stroke
- Prosthetic Heart Valves Triple Treatment
- Precision Medicine in Dual Antiplatelet Regimes Strategies (Deescalation, Escalation, Change Strategies for Dual Antiplatelet Therapy)
- De-Escalation Via a Duration of Dual Antiplatelet Treatment
- De-Escalation With Switching Between P2Y12 Inhibitors Drugs
- De-Escalation With Dose Reduction
- Escalation
- Change Between Prasugrel and Ticagrelor
- Triple Antithrombotic Therapy
- Precision Medicine on P2Y12 Inhibitors With Gene Testing Approach and Clopidogrel Resistance
- P2Y12 Receptor Gene Polymorphisms
- Conclusion
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
- Introduction
- Epidemiological Studies
- Structural and Functional Changes of Cardiac Tissue During Diabetes
- Role of Obesity in Diabetes and Cvd
- Role of Glycemic Control in Diabetes and Cvd
- Role of Dyslipidemia in Diabetes and Cvd
- Role of Hypertension in Diabetes and Cvd
- Biochemical Aspects Between Diabetes and Cvds
- Molecular Aspects Between Diabetes and Cvds
- Genetic Loci Linked With T2Dm and Cvd
- Dna Or Histone Modifications in T2Dm and Cvds
- Association of Hmga1 With T2Dm and Cvd Risk
- Association of Micrornas (Mirna) With T2Dm and Cvd Risk
- Association of Long Non-Coding Rna (Lncrnas) With T2Dm and Cvd Risk
- Primary Prevention of Cardiovascular Disease in Diabetes Mellitus
- Lessons Learned and Future Directions
- Conclusion
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
- Subject Index
Author
- M. Iqbal Choudhary
